Clovis Oncology Inc  

(Public, NASDAQ:CLVS)   Watch this stock  
56.62
+0.36 (0.64%)
After Hours: 57.48 +0.86 (1.52%)
Jan 18, 5:20PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 55.55 - 57.48
52 week 11.57 - 57.93
Open 56.30
Vol / Avg. 2.12M/2.65M
Mkt cap 2.55B
P/E     -
Div/yield     -
EPS -10.36
Shares 44.33M
Beta 2.06
Inst. own 95%
Feb 23, 2017
Q4 2016 Clovis Oncology Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 19, 2016
RubracaT (rucaparib) U.S. FDA Approval Call - Webcast
Nov 8, 2016
Clovis Oncology Inc at Credit Suisse Healthcare Conference
Nov 3, 2016
Q3 2016 Clovis Oncology Inc Earnings Call - Webcast
Nov 3, 2016
Q3 2016 Clovis Oncology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -60.81% -47.34%
Return on average equity -310.24% -111.62%
Employees 309 -
CDP Score - -

Address

5500 Flatiron Pkwy Unit 100
BOULDER, CO 80301-2834
United States - Map
+1-303-6255000 (Phone)
+1-303-2450360 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Officers and directors

M. James E. Barrett Ph.D. Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Patrick J. Mahaffy President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Daniel W. Muehl Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
Age: 53
Bio & Compensation  - Reuters
Gillian C. Ivers-Read Executive Vice President - Technical Operations, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
Lindsey Rolfe Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
C. Dale Hooks Senior Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Brian G. Atwood Independent Director
Age: 63
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 60
Bio & Compensation  - Reuters